Fatigue

Caffeine Powder Market to Reach $1,612.1 Million, Globally, by 2032 at 5.5% CAGR: Allied Market Research

Retrieved on: 
Monday, April 8, 2024
Alertness, Health, Fatigue, Headache, Growth, Data, Drink, Migraine, Caffeine, Medicinal plants

WILMINGTON, Del., April 8, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Caffeine Powder Market by Source (Synthetic Caffeine, Natural Caffeine), and Application (Food and Beverages, Pharmaceuticals, Cosmetics and Personal Care, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the "caffeine powder market" was valued at $949.4 million in 2022, and is estimated to reach $1,612.1 million by 2032, growing at a CAGR of 5.5% from 2023 to 2032.

Key Points: 
  • Moreover, caffeine powder offers consumers the flexibility to customize their caffeine intake according to their preferences and needs.
  • In addition, the globalization of the caffeine powder market has led to increased accessibility and availability of products across regions and channels.
  • Furthermore, Europe is home to several prominent pharmaceutical and food industries that utilize caffeine powder in various formulations, further bolstering market growth.
  • With its robust market infrastructure, consumer demand, and regulatory framework, Europe is expected to maintain its leadership position in the global caffeine powder market.

Caffeine Powder Market to Reach $1,612.1 Million, Globally, by 2032 at 5.5% CAGR: Allied Market Research

Retrieved on: 
Monday, April 8, 2024
Alertness, Health, Fatigue, Headache, Growth, Data, Drink, Migraine, Caffeine, Medicinal plants

WILMINGTON, Del., April 8, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Caffeine Powder Market by Source (Synthetic Caffeine, Natural Caffeine), and Application (Food and Beverages, Pharmaceuticals, Cosmetics and Personal Care, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the "caffeine powder market" was valued at $949.4 million in 2022, and is estimated to reach $1,612.1 million by 2032, growing at a CAGR of 5.5% from 2023 to 2032.

Key Points: 
  • Moreover, caffeine powder offers consumers the flexibility to customize their caffeine intake according to their preferences and needs.
  • In addition, the globalization of the caffeine powder market has led to increased accessibility and availability of products across regions and channels.
  • Furthermore, Europe is home to several prominent pharmaceutical and food industries that utilize caffeine powder in various formulations, further bolstering market growth.
  • With its robust market infrastructure, consumer demand, and regulatory framework, Europe is expected to maintain its leadership position in the global caffeine powder market.

STEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME

Retrieved on: 
Monday, April 8, 2024
Friends, New Drug Application, Elamipretide, Patient, Barth syndrome, NDA, Syndrome, Ultra, Quality of life, Safety, Muscle weakness, Stealth, Fatigue, FDA, Food, Medicine, Pharmaceutical industry

NEEDHAM, Mass., April 8, 2024 /PRNewswire/ -- Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration ("FDA") has accepted for filing its New Drug Application ("NDA") for elamipretide for the treatment of Barth syndrome. The NDA is supported by the positive data from the SPIBA-001 Phase 3 Natural History Control Study and additional supporting efficacy and safety data from the TAZPOWER Part 2 baseline-controlled trial. Elamipretide received Fast Track Designation in 2017, Orphan Drug Designation in 2018 and Rare Pediatric Disease Designation in 2020. 

Key Points: 
  • Elamipretide received Fast Track Designation in 2017, Orphan Drug Designation in 2018 and Rare Pediatric Disease Designation in 2020.
  • The FDA indicated that it is currently planning to hold an advisory committee meeting to discuss the application.
  • The application was assigned a standard review designation, which the Company has asked FDA to reconsider.
  • Elamipretide is also in development for primary mitochondrial myopathy, with pivotal data from the fully-enrolled Phase 3 NuPOWER trial expected in late 2024.

New survey uncovers lack of awareness around heart valve disease and risk factors among women

Retrieved on: 
Sunday, April 7, 2024
Diagnosis, Health, Cardiovascular disease, Ventricular septal defect, Organization, Prevalence, Coronary artery disease, Disease, Health equity, Risk, Patient, Ageing, Knowledge, Aortic stenosis, Research, Female, Medtronic, MD, Male, American College, TAVR, Fatigue, Dietary supplement

DUBLIN, April 7, 2024 /PRNewswire/ -- Medtronic plc, a global leader in healthcare technology, today unveiled topline findings of its comprehensive survey on women's perceptions and knowledge of risk factors, treatment patterns, and preventive care practices related to heart valve disease. The survey is endorsed by Women as One and was conducted by Wakefield Research sampling 1,000 women in the United States (U.S.) aged 50 and older.

Key Points: 
  • "Heart valve disease awareness deserves broader attention in the U.S., especially considering many women aged 50 and older are at an increased risk of developing the disease.
  • This survey shines a light on the need for increased awareness, early detection, and access to appropriate care for women."
  • Findings from the survey highlight:
    There is a lack of awareness among women about the risks of aortic stenosis (AS) and cardiovascular disease.
  • Despite the prevalence of cardiovascular disease amongst women, awareness is low, with 26% of women not having heard of any of the most common heart-related conditions such as coronary artery disease, congenital heart disease, heart valve disease, or AS, and only 30% of women aged 50 and older having heard of AS.

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

Retrieved on: 
Saturday, April 6, 2024
Guillain–Barré syndrome, Bone marrow, Medical College of Wisconsin, Encephalopathy, Survival, Immunotherapy, BCMA, Patient, Hypotension, Mortality, B-cell maturation antigen, Edema, Periodic breathing, Associate professor, Dexamethasone, Certification, Neutropenia, Dizziness, Risk, Headache, Chills, Myelodysplastic syndrome, Coagulopathy, DPD, Johnson & Johnson, Immune system, Effect, Fatigue, Thrombocytopenia, Food, Disease, Drive, Appetite, Lymphocytopenia, JNJ, Constipation, Multiple myeloma, Acute myeloid leukemia, CRS, Death, Hypersensitivity, Cytopenia, Cytokine release syndrome, ASCO, Use, Hematology, FDA, PVD, Annual general meeting, T cell, DSM-IV codes, Incidence, Tachycardia, Bortezomib, Diarrhea, Viral, Hope, United, Cough, Daratumumab, Nausea, Society, Division, Physician, Pharmaceutical industry

HORSHAM, Pa., April 5, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.

Key Points: 
  • "This milestone underscores our commitment to improve outcomes for patients and transform the treatment of multiple myeloma with CARVYKTI," said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine.
  • CARVYKTI® is a cell therapy that works by harnessing a patient's immune system, or T cells, to fight the disease.
  • Treatment requires extensive training, preparation, and certification to ensure a positive experience for patients.
  • Since initial approval in February 2022, Johnson & Johnson has made significant advances in manufacturing to rapidly scale CARVYKTI® production.

Diet and nutrition: how well Tanzanians eat depends largely on where they live

Retrieved on: 
Tuesday, April 9, 2024
Malnutrition, Telephone numbers in Hungary, Urbanization, Cardiovascular disease, Obesity, Vitamin, Nutrient, Bread, Groundnut, Potassium, Vegetable, Diabetes, Chapati, Calcium, Zinc, Research, Fats, Food, Mineral, Protein, Magnesium, City, Sugar, Diet, Niacin, Thiamine, Infection, Fruit, Snack, Calorie, Micronutrient, Fatigue, Iron, Dietary supplement

Across the continent the urban share of the total population is projected to increase to 50% by 2030 and 60% by 2050.

Key Points: 
  • Across the continent the urban share of the total population is projected to increase to 50% by 2030 and 60% by 2050.
  • Urbanisation is associated with lifestyle changes such as less physical activity and less labour-intensive work.
  • This is often accompanied by an increased intake of high-calorie fast foods, snacks, and sugar-sweetened beverages.

Food diaries

  • Using data from food diaries recorded by 1,506 households over a two-week period, I calculated how many calories, macronutrients and micronutrients were consumed and compared them to the recommended requirements for a healthy life.
  • Besides food diaries, our data also included information on household characteristics and their socioeconomic status.

Homegrown or highly processed?

  • This was because they were not eating sufficient quantities of food.
  • Most food was home-grown, which provided beneficial nutrients, but diets were not diverse enough to provide all the nutrients needed for healthy living.
  • At the opposite end of the scale, residents of Dar es Salaam also ate unhealthy diets, but for very different reasons.

Calories, nutrients or a lack thereof

  • Rural households primarily consumed starches, cereals, vegetables and fruit, making up 29%, 21%, 12% and 7% of their diet respectively.
  • Plantains, maize, cassava, sweet potatoes and spinach were the most consumed food items in rural areas.
  • Many of these nutrients are found in animal foods, which made up a small share of rural diets.
  • In terms of quantity, these households tended to consume more, leading to lower levels of nutritional deficiencies than in rural areas.
  • About 26% of households did not meet the recommended calorie intake, but this was significantly better than in rural areas.

Next steps

  • At the same time, overconsumption of potentially harmful food substances such as fats and sugars can lead to health risks such as obesity, diabetes and cardiovascular disease.
  • The findings highlight the need for a varied approach to dealing with nutrient intake and tackling problems such as rising obesity rates.


Hannah Ameye does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Lost for words? Research shows art therapy brings benefits for mental health

Retrieved on: 
Tuesday, April 9, 2024
Observational study, Depression, Health, First Nations, Mental health, Grief, Schizophrenia, Acute stress disorder, Environment, Mental, Post-traumatic stress disorder, Risk, Eating, Patient, Journal, Trauma, Research, Child, Magic, Anxiety, Cancer, Fatigue, Sculpture, Adolescence, Drawing, Regulation, Safety, Spectrum, Art therapy, Emotion, Palliative care, Dementia, Nursing

Art therapy uses creative processes, primarily visual art such as painting, drawing or sculpture, with a view to improving physical health and emotional wellbeing.

Key Points: 
  • Art therapy uses creative processes, primarily visual art such as painting, drawing or sculpture, with a view to improving physical health and emotional wellbeing.
  • Art therapy can be used to support treatment for a wide range of physical and mental health conditions.
  • In a study published this week in the Journal of Mental Health, we found art therapy was associated with positive outcomes for children and adolescents in a hospital-based mental health unit.

An option for those who can’t find the words

  • Where possible, after finishing an artwork, a person can explore the meaning of their work with the art therapist, translating unspoken symbolic material into verbal reflection.
  • However, as the talking component is less central to the therapeutic process, art therapy is an accessible option for people who may not be able to find the words to describe their experiences.
  • Art therapy has also been linked to improved outcomes for people with a range of physical health conditions.

Our research

  • While most care takes place in the community, a small proportion of young people require care in hospital to ensure their safety.
  • However, these “restrictive practices” are associated with negative effects such as post-traumatic stress for patients and health professionals.
  • Read more:
    'An arts engagement that's changed their life': the magic of arts and health

    Our research looked at more than six years of data from a child and adolescent mental health hospital ward in Australia.

  • Confirming the effect of a therapeutic intervention requires controlled clinical trials where people are randomly assigned one treatment or another.
  • Although ours was an observational study, randomised controlled trials support the benefits of art therapy in youth mental health services.

What do young people think?

  • In previous research we found art therapy was considered by adolescents in hospital-based mental health care to be the most helpful group therapy intervention compared to other talk-based therapy groups and creative activities.
  • In research not yet published, we’re speaking with young people to better understand their experiences of art therapy, and why it might reduce distress.

A promising area


The burgeoning research showing the benefits of art therapy for both physical and especially mental health highlights the value of creative and innovative approaches to treatment in health care. There are opportunities to expand art therapy services in a range of health-care settings. Doing so would enable greater access to art therapy for people with a variety of physical and mental health conditions.

  • She has received funding from the Health Education and Training Institute (HETI) for the Mental Health Research Award.
  • Iain Perkes works for the University of New South Wales and the Sydney Children's Hospitals Network which is part of NSW Health.
  • He is affiliated with Neuroscience Research Australia (NeuRA) and the Health Education and Training Institute (HETI, NSW Health).

Orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta Treatment of Gaucher disease, 21/08/2020 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Brain, B cell, Gaucher's disease, Cell, CD34, Bone marrow, Bleeding, Disease, Seizure, Bruise, Patient, Committee, Knowledge, Fracture, Spleen, Regulation, Fatigue, Autotransplantation, EMA, IRIS, Human, Life expectancy, Eye, Bone pain, Anemia, European, COMP, Sponsor, European Commission, Safety, PPD, Marketing, Liver, Medicine, Pharmaceutical industry

Orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta Treatment of Gaucher disease, 21/08/2020 Positive

Key Points: 


Orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta Treatment of Gaucher disease, 21/08/2020 Positive

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 25, 2024
Rated R, Fulvestrant, KICKSTART, Patient, Sale, G&A, Investment, Therapy, Anemia, Vomiting, Artificial intelligence, Effector, Research, Science, AML, Expense, Pembrolizumab, Breast cancer, Safety, Fatigue, PD-L1, Database, NSCLC, Associate, Cancer, University, PFS, Hematology, FDA, OS, Azacitidine, ZF, Administration, Assistant, MNK, Progression-free survival, COVID-19, Fast Track, Messenger, Cell, Nausea, Research and development, DARPA, Interval (mathematics), Pharmaceutical industry

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • The primary analysis will reflect 37 PFS events, which provides approximately 80% power to detect a PFS hazard ratio of 0.65 at a p≤0.2.
  • Revenue: Revenue was zero for the quarter ended December 31, 2023, compared to approximately $0.7 million for the same quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses were $6.1 million for the quarter ended December 31, 2023, compared to $6.6 million for the same quarter of 2022.
  • The earn-out period expired in August 2023 resulting in a reduction of the corresponding earn-out liability to zero as of December 31, 2023.

Nametag Launches Self-Service Account Recovery Solution That Stops AI-Generated Deepfake Attacks

Retrieved on: 
Monday, March 25, 2024
Failure, HubSpot, Microsoft, Organization, MFA, Risk management, IAD, Science, Partnership, Help desk, PAD, Deepfake, AI, SSPR, Atos, Okta, Machine learning, Fatigue, Zendesk

SEATTLE, March 25, 2024 (GLOBE NEWSWIRE) -- Nametag, the identity verification platform for helpdesks, today announced the launch of Nametag Autopilot, the only self-service account recovery solution that prevents AI-generated deepfake attacks. Account recovery requests represent a significant single point of failure in IT security, susceptible to ransomware, data breaches, and injection attacks, including the use of AI deepfakes. Nametag Autopilot prevents social engineering and impersonation attacks while saving organizations millions by deflecting expensive password and multifactor authentication (MFA) resets to self-service.

Key Points: 
  • HubSpot taps Nametag to secure helpdesk operations, inspire trust, and improve user experience
    SEATTLE, March 25, 2024 (GLOBE NEWSWIRE) -- Nametag , the identity verification platform for helpdesks, today announced the launch of Nametag Autopilot , the only self-service account recovery solution that prevents AI-generated deepfake attacks.
  • So when a helpdesk agent grants an account reset, they inadvertently blow the door wide open to data breaches and ransomware attacks.
  • In this way, Nametag stops account takeovers (ATOs) and data breaches by verifying users at critical moments like account recoveries, MFA resets, and high-risk transactions.
  • “I am excited about our new partnership with Nametag for its account recovery solution as it promises to elevate our customer experience to new heights.